Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells revolutionizes the functional genomics landscape. The study showcases the potential of CRISPR technology to systematically interrogate gene function on a genome-wide scale. By delivering a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeting over 18,000 genes with 64,000 unique guide sequences, both negative and positive selection screenings in human cells become feasible. The GeCKO library not only identified essential genes for cell viability in cancer and stem cells but also uncovered genes involved in resistance to therapeutic agents like vemurafenib in melanoma models. This approach demonstrated high consistency between guide RNAs targeting the same gene and a significant hit confirmation rate, underscoring the promise of genome-scale screening with Cas9.
Since the completion of the Human Genome Project, one of the primary goals has been to functionally characterize all annotated genetic elements in normal biological processes and diseases. While RNA interference (RNAi) has been the predominant method for genome-wide loss-of-function screening in mammalian cells, its utility is constrained by incomplete protein depletion and off-target effects. The emergence of the CRISPR-associated nuclease Cas9 has provided an effective tool for introducing targeted loss-of-function mutations in the genome. Cas9 can be precisely programmed to induce double-strand breaks at specific genomic loci through a synthetic guide RNA, allowing the creation of loss-of-function alleles. The specificity of Cas9’s targeting enables the exploration of its potential for pooled genome-scale functional screening.
The efficacy of gene knockout by lentiCRISPR transduction was validated through the comprehensive knockdown of a target gene like enhanced green fluorescent protein (EGFP). The study showed that lentiCRISPRs could abolish EGFP fluorescence in a high percentage of cells, emphasizing the efficiency of this delivery system. The design of the GeCKO library, targeting thousands of genes in the human genome with multiple guide sequences per gene, enabled successful negative selection screening by profiling the depletion of sgRNAs targeting essential survival genes. The GeCKO approach not only identified essential genes but also pinpointed gene targets involved in negative selection screens.
In the realm of positive selection screening, GeCKO proved its utility by identifying gene knockouts that conferred resistance to the BRAF protein kinase inhibitor vemurafenib in melanoma. The study revealed several novel hits, including genes like NF2, CUL3, and members of the STAGA histone acetyltransferase complex, shedding light on potential mechanisms of drug resistance. The comparison between genome-scale shRNA screening and GeCKO highlighted the superior consistency and reliability of the latter, emphasizing the potential of Cas9:sgRNA-based technology to revolutionize functional genomics.
GeCKO screening offers a mechanistically distinct approach compared to RNAi, introducing loss-of-function mutations directly into genomic DNA. The high screening sensitivity achieved through homozygous knockout and the ability to target elements across the entire genome set GeCKO apart from RNAi. The study demonstrated that GeCKO screens hold immense potential to transform functional genomics by offering an efficient method to perturb gene function systematically. The validation of top-ranking genes from the GeCKO screens further emphasized the reliability and efficacy of this approach in identifying key genetic elements.
In conclusion, Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells represents a breakthrough in functional genomics, offering a powerful tool to unravel the complexities of gene function on a genome-wide scale. The study’s findings underscore the efficiency, reliability, and transformative potential of Cas9:sgRNA-based technology in deciphering the functional landscape of the human genome. As the field of CRISPR-based screening continues to evolve, GeCKO screening stands out as a promising approach with broad implications for understanding gene function in health and disease.
- CRISPR-Cas9 GeCKO screening enables systematic interrogation of gene function on a genome-wide scale.
- The study showcases high consistency and hit confirmation rates, highlighting the promise of Cas9-based genome-scale screening.
- GeCKO screening offers a mechanistically distinct method to RNAi, introducing loss-of-function mutations directly into genomic DNA.
- Comparison with shRNA screening demonstrates the superior consistency and reliability of GeCKO, underscoring its potential to transform functional genomics.
- The validation of GeCKO screen hits emphasizes the efficacy and reliability of this approach in identifying key genetic elements.
Tags: regulatory
Read more on pmc.ncbi.nlm.nih.gov